{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:36:39Z","timestamp":1793723799160,"version":"4.6.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The TAFA-CRUZ study evaluated the real-world effectiveness and safety of tafamidis 61 mg in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure. The primary objective was to evaluate all-cause mortality, with key secondary outcomes including 30-month survival, cardiovascular-related deaths, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, single-center observational study included 238 patients with ATTR-CM followed between 2019 and 2024 in a structured amyloidosis program. Of these patients, 140 were initiated on tafamidis 61 mg in additional to receiving supportive care guided by the CHAD-STOP strategy, while 98 received only supportive care. Baseline demographics, outcomes, and subgroup analyses, including National Amyloidosis Centre (NAC) stages, were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort was predominantly elderly (mean age, 81.8 years) and male (80.7%). Patients treated with tafamidis were, on average, younger and less symptomatic at baseline than those in the comparator group. After a median follow-up of 21 months, treatment with tafamidis, as compared to supportive care alone, was associated with lower all-cause mortality (16.4% vs 54.1%) and cardiovascular mortality (13.6% vs 39.8%). Thirty-month survival was significantly higher in the tafamidis group (92.1% vs 51.0%; hazard ratio [HR], 0.17 [95% CI, 0.10-0.32]; P &amp;lt; 0.001). Survival benefits were consistent across all NAC stages, with the greatest relative effect observed in NAC stage 3. Tafamidis was well tolerated, with adverse events mostly limited to mild transient gastrointestinal symptoms and rare treatment discontinuations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort, treatment with tafamidis 61 mg was effective and safe, being associated with significantly reduced all-cause and cardiovascular mortality across all disease stages. These findings extend clinical trial evidence into routine practice and highlight the value of specialized amyloidosis programs in optimizing outcomes for patients with ATTR-CM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag106","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T11:27:46Z","timestamp":1775388466000},"page":"845-855","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of transthyretin amyloid cardiomyopathy with tafamidis 61 mg\u2014Real-world data from a tertiary center (TAFA-CRUZ study)"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9672-9928","authenticated-orcid":false,"given":"Rita","family":"Almeida Carvalho","sequence":"first","affiliation":[{"name":"Cardiology Department and Cardiomyopathy Unit, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Amador","sequence":"additional","affiliation":[{"name":"Cardiology Department and Cardiomyopathy Unit, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Malt\u00eas","sequence":"additional","affiliation":[{"name":"Cardiology Department and Cardiomyopathy Unit, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gon\u00e7alo","family":"Cunha","sequence":"additional","affiliation":[{"name":"Cardiology Department and Cardiac Rehabilitation Department, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Marques","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Laranjeira","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Br\u00edzido","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mendes","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Cardiology Department and Cardiomyopathy Unit, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno M","family":"Rocha","sequence":"additional","affiliation":[{"name":"Cardiology Department and Cardiomyopathy Unit, Hospital de Santa Cruz, Unidade Local de Sa\u00fade Lisboa Ocidental , Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"1","key":"2026080419563894600_zxag106-B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","article-title":"Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review","volume":"20","author":"Delgado","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"2026080419563894600_zxag106-B2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2026080419563894600_zxag106-B3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13023-023-02933-w","article-title":"Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases","volume":"18","author":"Damy","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"2026080419563894600_zxag106-B4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"2026080419563894600_zxag106-B5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2026080419563894600_zxag106-B6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"31","author":"Garcia-Pavia","year":"2025","journal-title":"J Card Fail"},{"key":"2026080419563894600_zxag106-B7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/JMDH.S160029","article-title":"Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade","year":"2018","journal-title":"J Multidiscip Healthc"},{"issue":"5","key":"2026080419563894600_zxag106-B8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real world evidence: neither magic nor myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2026080419563894600_zxag106-B9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis using 99 m Tc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"2026080419563894600_zxag106-B10","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"21","key":"2026080419563894600_zxag106-B11","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac amyloidosis","volume":"74","author":"Ternacle","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"2026080419563894600_zxag106-B12","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"36","key":"2026080419563894600_zxag106-B13","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"2026080419563894600_zxag106-B14","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"30","key":"2026080419563894600_zxag106-B15","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080419563894600_zxag106-B16","author":"Eurostat"},{"key":"2026080419563894600_zxag106-B17","doi-asserted-by":"publisher","first-page":"133522","DOI":"10.1016\/j.ijcard.2025.133522","article-title":"Impact of tafamidis on survival in elderly patients: insights from the Healthcare European Amyloidosis Registry","volume":"437","author":"Jobb\u00e9-Duval","year":"2025","journal-title":"Int J Cardiol"},{"issue":"2","key":"2026080419563894600_zxag106-B18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/ehf2.15126","article-title":"Real-world characteristics and treatment of cardiac transthyretin amyloidosis: a multicentre, observational study","volume":"12","author":"Nies","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026080419563894600_zxag106-B19","doi-asserted-by":"publisher","first-page":"863179","DOI":"10.3389\/fcvm.2022.863179","article-title":"Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond","volume":"9","author":"Irabor","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"2026080419563894600_zxag106-B20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2026080419563894600_zxag106-B21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"2026080419563894600_zxag106-B22","doi-asserted-by":"publisher","first-page":"e012112","DOI":"10.1161\/CIRCHEARTFAILURE.124.012112","article-title":"Changing treatment landscape in transthyretin cardiac amyloidosis","volume":"18","author":"Fontana","year":"2025","journal-title":"Circ Heart Fail"},{"issue":"8","key":"2026080419563894600_zxag106-B23","doi-asserted-by":"publisher","first-page":"102549","DOI":"10.1016\/j.jchf.2025.102549","article-title":"Outcome and disease progression in NYHA functional class I and II patients with wild-type transthyretin cardiomyopathy treated with tafamidis","volume":"13","author":"Sinigiani","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026080419563894600_zxag106-B24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3696","article-title":"Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage","volume":"9","author":"Damy","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2026080419563894600_zxag106-B25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM Trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"issue":"10","key":"2026080419563894600_zxag106-B26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2026080419563894600_zxag106-B27","doi-asserted-by":"publisher","first-page":"13691","DOI":"10.1038\/s41598-024-64697-y","article-title":"Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system","volume":"14","author":"Wu","year":"2024","journal-title":"Sci Rep"},{"issue":"7","key":"2026080419563894600_zxag106-B28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/03007995.2025.2534468","article-title":"Empowering patients through pharmacovigilance, transparency, and health literacy: a narrative review","volume":"41","author":"De Jesus","year":"2025","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"2026080419563894600_zxag106-B29","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026080419563894600_zxag106-B30","doi-asserted-by":"publisher","first-page":"101568","DOI":"10.1016\/j.jacadv.2024.101568","article-title":"Accuracy of established prognostic staging systems for cardiac transthyretin amyloidosis in the tafamidis era","volume":"4","author":"M\u00fcller","year":"2025","journal-title":"JACC Adv"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag106\/67929628\/zxag106.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/16\/845\/67929628\/zxag106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/16\/845\/67929628\/zxag106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:56:44Z","timestamp":1785887804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/16\/845\/8625797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":30,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag106","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,4,7]]}}}